Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03418-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Yuanliang Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China. Hauptthemen laut MEDLINE: Bevacizumab, ErbB Receptors, Brain Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taishan Scholars Program of Shandong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
This study aimed to determine whether the combined use of bevacizumab could improve overall survival (OS) in patients with brain metastasis (BM), epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) undergoing cerebral radiotherapy. Materials and methods A total of 237 patients with EGFR-mutant lung adenocarcinoma and BM met the inclusion criteria for this retrospective study, including 102 patients in the bevacizumab treatment group and 135 in the non-bevacizumab group. The Kaplan–Meier method was used for survival analysis. Univariate and multivariate analyses were performed to identify EGFR-mutated BM prognostic factors for these patients.
Results
At the end of the last follow-up period, 176 patients (74.3%) had died, and the median overall survival (OS) was 34.2 months. We observed a significant difference in the median OS between the bevacizumab and non-bevacizumab groups (45.8 months vs 30.0 months, P < 0.0001). Among the 178 (75.1%) patients who received cerebral radiotherapy, the median OS of patients in the bevacizumab + cerebral radiotherapy group was 45.8 months versus 32.0 months in the non-bevacizumab + cerebral radiotherapy group, respectively ( P = 0.0007). Patients treated with bevacizumab after cerebral radiotherapy had a longer median OS than patients treated with bevacizumab before cerebral radiotherapy (59.4 months vs 33.7 months, P = 0.0198). In the univariate analysis, smoking status, Lung-molGPA scores, and bevacizumab therapy showed correlations (HR = 1.450, P = 0.045; HR = 0.700, P = 0.023; HR = 0.499, P < 0.001). Multivariate analysis showed that bevacizumab therapy alone (hazard ratio [HR] = 0.514; P < 0.001) was independently associated with improved OS.
Conclusion
In patients with BM from EGFR-mutated NSCLC, cerebral radiotherapy with bevacizumab markedly improved OS. This improvement was more evident after cerebral radiotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, People's Republic of China.
- The People's Hospital of Zhangqiu Area, Jinan, People's Republic of China.
- Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China. lijianbin@msn.com.
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, People's Republic of China. lijianbin@msn.com.
- Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, People's Republic of China. Lizx0108@163.com.
Förderung
- Taishan Scholars Program of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y., Li, J., Li, Y., Deng, G., Wang, Q., Qin, H., Li, J., & Li, Z. (2024). Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03418-3
Vancouver
Zhou Y, Li J, Li Y, Deng G, Wang Q, Qin H, et al. Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03418-3
BibTeX
@article{Zhou2024,
author = {Zhou, Yuanliang and Li, Jingchao and Li, Yankang and Deng, Guangchuan and Wang, Qi and Qin, Hongyue and Li, Jianbin and Li, Zhenxiang},
title = {Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03418-3}
}
EUVIMED